Drug Ther Bull. 1999 Aug;37(8):57-8. doi: 10.1136/dtb.1999.37857.
Deflazacort (Calcort--Shire) is an oral corticosteroid licensed for use in adults and children. When deflazacort first became available last year, the manufacturer claimed that the drug had a lower incidence of steroid-induced unwanted effects compared with prednisolone. However, this claim was later withdrawn at the request of the Medicines Control Agency following its review of the cited data. Current promotional material claims simply that deflazacort is "a new choice of oral steroid". Here we discuss whether deflazacort offers any advantages over established corticosteroid therapy.
地夫可特（Calcort--施贵宝公司）是一种口服皮质类固醇药物，已获许可用于成人和儿童。去年地夫可特首次上市时，制造商声称与泼尼松龙相比，该药物引起类固醇不良反应的发生率较低。然而，在药品管理局对引用数据进行审查后，这一说法随后应其要求被撤回。目前的促销材料仅称地夫可特是“口服类固醇的一种新选择”。在此，我们讨论地夫可特是否比既定的皮质类固醇疗法具有任何优势。
